Showing results (31-40 of 80) with videos related to
Sort By:
Pageof 8
Cancer Research|July 4, 2015
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Thomas A Paul, Parantu K Shah, et al.Scientific Reports|October 22, 2020
Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancerReid T Powell, Abena Redwood, Xuan Liu, et al.Cancer Cell|July 12, 2011
Proinvasion metastasis drivers in early-stage melanoma are oncogenesKenneth L Scott, Cristina Nogueira, Timothy P Heffernan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic CancerDonastas Sakellariou-Thompson, Marie-Andrée Forget, Caitlin Creasy, et al.Biorxiv : the Preprint Server for Biology|February 24, 2023
Oncogenic Kras G12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 + T cells dependent mannerKrishnan K Mahadevan, Kathleen M McAndrews, Valerie S LeBleu, et al.Cancer Cell|August 25, 2023
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cellsKrishnan K Mahadevan, Kathleen M McAndrews, Valerie S LeBleu, et al.Cancer Research|March 5, 2015
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancerPiergiorgio Pettazzoni, Andrea Viale, Parantu Shah, et al.Cell|September 6, 2011
BET bromodomain inhibition as a therapeutic strategy to target c-MycJake E Delmore, Ghayas C Issa, Madeleine E Lemieux, et al.Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.Biorxiv : the Preprint Server for Biology|October 3, 2023
Evolutionary fingerprints of EMT in pancreatic cancersLuigi Perelli, Li Zhang, Sarah Mangiameli, et al.Pageof 8